MA42795A - Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih - Google Patents

Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih

Info

Publication number
MA42795A
MA42795A MA042795A MA42795A MA42795A MA 42795 A MA42795 A MA 42795A MA 042795 A MA042795 A MA 042795A MA 42795 A MA42795 A MA 42795A MA 42795 A MA42795 A MA 42795A
Authority
MA
Morocco
Prior art keywords
prophylactic
hiv virus
virus infection
useful
therapeutic
Prior art date
Application number
MA042795A
Other languages
English (en)
Other versions
MA42795B1 (fr
Inventor
Michael Graupe
Steven J Henry
John O Link
Charles William Rowe
Roland D Saito
Scott D Schroeder
Dimitrios Stefanidis
Winston C Tse
Jennifer R Zhang
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=59714166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA42795(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of MA42795A publication Critical patent/MA42795A/fr
Publication of MA42795B1 publication Critical patent/MA42795B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/02—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms
    • C07C317/08—Sulfones; Sulfoxides having sulfone or sulfoxide groups bound to acyclic carbon atoms of an acyclic unsaturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne un composé de formule (ia), (ib), (iia), et (iib) : (ia) (ib) (iia) (iib) qui sont utiles dans le traitement d'une infection virale par retroviridae incluant une infection provoquée par le virus du vih.
MA42795A 2016-08-19 2017-08-17 Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih MA42795B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662377312P 2016-08-19 2016-08-19
US201762457555P 2017-02-10 2017-02-10
PCT/US2017/047416 WO2018035359A1 (fr) 2016-08-19 2017-08-17 Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih

Publications (2)

Publication Number Publication Date
MA42795A true MA42795A (fr) 2019-07-03
MA42795B1 MA42795B1 (fr) 2019-08-30

Family

ID=59714166

Family Applications (2)

Application Number Title Priority Date Filing Date
MA050673A MA50673A (fr) 2016-08-19 2017-08-17 Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus vih
MA42795A MA42795B1 (fr) 2016-08-19 2017-08-17 Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA050673A MA50673A (fr) 2016-08-19 2017-08-17 Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus vih

Country Status (43)

Country Link
US (4) US10071985B2 (fr)
EP (3) EP3347352B1 (fr)
JP (5) JP6716785B2 (fr)
KR (5) KR20240070646A (fr)
CN (3) CN119462611A (fr)
AU (5) AU2017312102B2 (fr)
BR (2) BR112018071678B1 (fr)
CA (1) CA3021227C (fr)
CL (1) CL2019000415A1 (fr)
CO (1) CO2019001379A2 (fr)
CR (1) CR20190084A (fr)
CY (2) CY1122296T1 (fr)
DK (2) DK3597646T3 (fr)
DO (1) DOP2019000033A (fr)
EC (1) ECSP19011209A (fr)
ES (2) ES2954514T3 (fr)
FI (1) FI3597646T3 (fr)
FR (1) FR22C1063I2 (fr)
HK (1) HK1256904B (fr)
HR (1) HRP20231018T1 (fr)
HU (3) HUE063811T2 (fr)
IL (1) IL264644B (fr)
JO (2) JOP20180098A1 (fr)
LT (3) LT3597646T (fr)
LU (1) LUC00292I2 (fr)
MA (2) MA50673A (fr)
MX (1) MX369307B (fr)
MY (1) MY191466A (fr)
NL (1) NL301212I2 (fr)
NO (1) NO2022059I1 (fr)
NZ (1) NZ750706A (fr)
PE (2) PE20190910A1 (fr)
PH (2) PH12021552802A1 (fr)
PL (2) PL3347352T3 (fr)
PT (2) PT3597646T (fr)
SA (1) SA519401123B1 (fr)
SG (2) SG10201912535VA (fr)
SI (2) SI3597646T1 (fr)
TW (5) TWI853404B (fr)
UA (1) UA121630C2 (fr)
UY (1) UY37367A (fr)
WO (1) WO2018035359A1 (fr)
ZA (1) ZA201901430B (fr)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
CN119462611A (zh) 2016-08-19 2025-02-18 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
TWI687415B (zh) * 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ， インコーポレイテッド ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
EP3752496B1 (fr) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Procédés et intermédiaires pour préparer un composé thérapeutique utile dans le traitement d'une infection virale par retroviridae
US20210115061A1 (en) * 2018-06-21 2021-04-22 Drexel University Small-Molecule HIV-1 Capsid Protein Inhibitors and Methods Using Same
KR20210033492A (ko) * 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
EP3833436A1 (fr) * 2018-08-09 2021-06-16 VIIV Healthcare UK (No.5) Limited Inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP3849982A1 (fr) 2018-09-14 2021-07-21 VIIV Healthcare UK (No.5) Limited Inhibiteurs de la réplication du virus de l'immunodéficience humaine
JP7433303B2 (ja) 2018-09-20 2024-02-19 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
EP3870174B1 (fr) * 2018-10-22 2023-11-01 Board of Regents of the University of Nebraska Promédicaments antiviraux et nanoformulations de ceux-ci
ES2971987T3 (es) * 2018-10-24 2024-06-10 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de inmunodeficiencia humana
US11541055B2 (en) 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
JP7500555B2 (ja) 2018-10-25 2024-06-17 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
EP3873607B1 (fr) * 2018-10-29 2023-11-29 VIIV Healthcare UK (No.5) Limited Dérivés de quinazolinyle-indazole et leur utilisation en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
JP2022506399A (ja) 2018-11-05 2022-01-17 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド ヒト免疫不全ウイルス複製の阻害剤
US20210395248A1 (en) * 2018-11-05 2021-12-23 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
EP3914604B1 (fr) 2019-01-25 2026-03-04 Brown University Compositions comprenant du censavudine ou de l'elvucitabine pour le traitement de l'inflammation et des troubles associés à l'âge
UY38559A (es) 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
MY201239A (en) 2019-03-22 2024-02-13 Gilead Sciences Inc Bridged tricyclic carbamoylpyridone compounds and their pharmaceutical use
US20220211704A1 (en) 2019-04-30 2022-07-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
RU2717101C1 (ru) 2019-06-03 2020-03-18 Андрей Александрович Иващенко Анелированные 9-гидрокси-1,8-диоксо-1,3,4,8-тетрагидро-2Н-пиридо[1,2-a]пиразин-7-карбоксамиды - ингибиторы интегразы ВИЧ, способы их получения и применения
BR112021025655A2 (pt) * 2019-06-19 2022-02-01 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
EP4038064B1 (fr) * 2019-10-01 2024-02-21 VIIV Healthcare UK (No.5) Limited Dérivés de 6-oxo-1,6-dihydropyrimidine-2-yl n-substitués utilisés en tant qu'inhibiteurs de la réplication du virus de l'immunodéficience humaine
EP4038068A1 (fr) 2019-10-01 2022-08-10 VIIV Healthcare UK (No.5) Limited Dérivés de-4-oxo-3,4-dihydropyrido[2,3-d]pyrimidin-2-yle n-substitués utilisés comme inhibiteurs de la réplication du virus de l'immunodéficience humaine
TW202128648A (zh) 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
US20220370451A1 (en) 2019-10-08 2022-11-24 VIIV HEALTHCARE UK ( No. 5) LIMITED Inhibitors of human immunodeficiency virus replication
CA3157275C (fr) * 2019-11-26 2026-02-10 Gilead Sciences, Inc. Inhibiteurs de capside pour la prevention du vih
EP4066839A4 (fr) 2019-11-28 2023-12-27 Shionogi & Co., Ltd Agent pharmaceutique prophylactique et thérapeutique pour maladies infectieuses à vih, caractérisé en ce qu'il comprend une combinaison d'un inhibiteur d'intégrase et d'un agent anti-vih
BR112022010204A2 (pt) 2019-11-29 2022-09-06 Jiangsu Hengrui Medicine Co Derivado do anel de piridina fusionado, método de preparação para o mesmo e uso farmacêutico do mesmo
CN113304166B (zh) * 2020-02-27 2022-10-14 河南真实生物科技有限公司 核苷类化合物在制备治疗冠状病毒感染性疾病的药物中的用途
KR20220151655A (ko) 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
EP4114527A1 (fr) 2020-03-06 2023-01-11 VIIV Healthcare UK (No.5) Limited Inhibiteurs de la réplication du virus de l'immunodéficience humaine
WO2021188959A1 (fr) 2020-03-20 2021-09-23 Gilead Sciences, Inc. Promédicaments de nucléosides de 4'-c-substitué-2-halo-2'-désoxyadénosine et leurs procédés de fabrication et d'utilisation
BR112022020933A2 (pt) 2020-04-15 2022-12-06 Viiv Healthcare Uk No 5 Ltd Inibidores de replicação do vírus da imunodeficiência humana
EP4153181A1 (fr) 2020-05-21 2023-03-29 Gilead Sciences, Inc. Compositions pharmaceutiques contenant du bictégravir
TWI858267B (zh) * 2020-06-25 2024-10-11 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑
TW202406932A (zh) 2020-10-22 2024-02-16 美商基利科學股份有限公司 介白素2-Fc融合蛋白及使用方法
PL4244396T3 (pl) 2020-11-11 2025-12-22 Gilead Sciences, Inc. Sposoby identyfikacji pacjentów z hiv wrażliwych na terapię przeciwciałami skierowanymi na miejsce wiązania cd4 gp120
EP4281083A4 (fr) 2021-01-25 2025-01-01 Brii Biosciences, Inc. Polythérapie contre le vih comprenant un dérivé d'adénosine et des inhibiteurs de capside
CN118159529A (zh) 2021-05-28 2024-06-07 江苏恒瑞医药股份有限公司 一种稠合吡啶环衍生物的可药用盐、晶型及其制备方法
KR20230018690A (ko) 2021-07-30 2023-02-07 (주) 에빅스젠 둥근이질풀 추출물을 유효성분으로 포함하는, 바이러스성 질환 치료 및 개선용 조성물
KR20230019059A (ko) 2021-07-30 2023-02-07 (주) 에빅스젠 연전초 추출물을 유효성분으로 포함하는, 바이러스성 질환 완화 및 개선용 조성물
MX2024004551A (es) * 2021-10-13 2024-06-26 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicacion del virus de inmunodeficiencia humana.
US12404262B2 (en) 2021-12-03 2025-09-02 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
CR20240223A (es) 2021-12-03 2024-07-08 Gilead Sciences Inc Compuestos terapéuticos para la infección por el virus del vih
US12084467B2 (en) 2021-12-03 2024-09-10 Gilead Sciences, Inc. Therapeutic compounds for HIV virus infection
TW202446773A (zh) 2022-04-06 2024-12-01 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
TWI867601B (zh) * 2022-07-01 2024-12-21 美商基利科學股份有限公司 可用於ｈｉｖ病毒感染之疾病預防性或治療性治療的治療性化合物
AU2023330037A1 (en) 2022-08-26 2025-03-06 Gilead Sciences, Inc. Dosing and scheduling regimen for broadly neutralizing antibodies
US20240226130A1 (en) 2022-10-04 2024-07-11 Gilead Sciences, Inc. 4'-thionucleoside analogues and their pharmaceutical use
KR20240061218A (ko) 2022-10-31 2024-05-08 주식회사 이보드 복합 단열재 및 제조방법
CR20250310A (es) 2023-01-30 2025-08-25 Merck Sharp & Dohme Llc Profármacos de inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4'
US20240390349A1 (en) 2023-04-19 2024-11-28 Gilead Sciences, Inc. Dosing regimen of capsid inhibitor
CN121219281A (zh) 2023-05-31 2025-12-26 吉利德科学公司 用于治疗hiv的化合物的固体形式
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
CN121399106A (zh) 2023-05-31 2026-01-23 吉利德科学公司 制备hiv衣壳抑制剂的方法
CN116675675A (zh) * 2023-06-05 2023-09-01 北京康立生医药技术开发有限公司 一种艾滋病治疗药物来那卡帕韦中间体化合物的制备方法
CN121335877A (zh) 2023-06-15 2026-01-13 Viiv保健英国第五有限公司 用于制备化合物的方法和中间体
WO2025029247A1 (fr) 2023-07-28 2025-02-06 Gilead Sciences, Inc. Régime hebdomadaire de lénacapavir pour le traitement et la prévention du vih
SI4531816T1 (sl) 2023-08-15 2026-04-30 Gilead Sciences, Inc. Farmacevtske formulacije biktegravirja in lenakapavirja
EP4529922A1 (fr) 2023-09-29 2025-04-02 Gilead Sciences, Inc. Formulations pharmaceutiques de bictégravir et de lenacapavir
WO2025042394A1 (fr) 2023-08-23 2025-02-27 Gilead Sciences, Inc. Schéma posologique d'un inhibiteur de capside du vih
KR20250040288A (ko) 2023-09-15 2025-03-24 민영호 복합 단열재
US20250122219A1 (en) 2023-10-11 2025-04-17 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202515549A (zh) 2023-10-11 2025-04-16 美商基利科學股份有限公司 橋聯三環胺甲醯基吡啶酮化合物及其用途
US20250127801A1 (en) 2023-10-11 2025-04-24 Gilead Sciences, Inc. Bridged tricyclic carbamoylpyridone compounds and uses thereof
US20250230163A1 (en) 2023-12-22 2025-07-17 Gilead Sciences, Inc. Solid forms of hiv integrase inhibitors
TW202547514A (zh) 2024-02-05 2025-12-16 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
WO2025184452A1 (fr) 2024-03-01 2025-09-04 Gilead Sciences, Inc. Formes solides d'inhibiteurs de l'intégrase du vih
US20250296932A1 (en) 2024-03-01 2025-09-25 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
US20250333424A1 (en) 2024-03-01 2025-10-30 Gilead Sciences, Inc. Antiviral compounds
US20250367385A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
WO2025240387A1 (fr) 2024-05-14 2025-11-20 Gilead Sciences, Inc. Injections médicales et dispositifs et procédés associés
US20250367386A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
US20250367382A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
US20250367381A1 (en) 2024-05-14 2025-12-04 Gilead Sciences, Inc. Medical injections and related devices and methods
US20260007683A1 (en) 2024-06-14 2026-01-08 Gilead Sciences, Inc. Pharmaceutical compositions comprising hiv integrase inhibitors
WO2025264995A1 (fr) * 2024-06-21 2025-12-26 Gilead Sciences, Inc. Formulations d'un inhibiteur de capside du vih
WO2026006521A1 (fr) 2024-06-27 2026-01-02 Gilead Sciences, Inc. Formulations de comprimés oraux
WO2026020086A1 (fr) 2024-07-19 2026-01-22 Gilead Sciences, Inc. Méthodes et formulations pharmaceutiques pour le traitement d'infections virales
WO2026076265A1 (fr) 2024-10-03 2026-04-09 Gilead Sciences, Inc. Thérapie de combinaison comprenant des composés de carbamoylpyridone tricycliques pontés et des inhibiteurs de la p-glycoprotéine

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816570A (en) 1982-11-30 1989-03-28 The Board Of Regents Of The University Of Texas System Biologically reversible phosphate and phosphonate protective groups
US4968788A (en) 1986-04-04 1990-11-06 Board Of Regents, The University Of Texas System Biologically reversible phosphate and phosphonate protective gruops
EP0533833B1 (fr) 1990-06-13 1995-12-20 GLAZIER, Arnold Promedicaments phosphoreux
EP0481214B1 (fr) 1990-09-14 1998-06-24 Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic Pro-médicaments dérivés de phosphonates
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5935946A (en) 1997-07-25 1999-08-10 Gilead Sciences, Inc. Nucleotide analog composition and synthesis method
US20020119443A1 (en) 2000-07-21 2002-08-29 Gilead Sciences, Inc. Prodrugs of phosphonate nucleotide analogues and methods for selecting and making same
JP4357293B2 (ja) 2001-06-27 2009-11-04 スミスクライン ビーチャム コーポレーション ジペプチジルペプチダーゼ阻害剤としてのフルオロピロリジン類
ATE380175T1 (de) 2001-06-27 2007-12-15 Smithkline Beecham Corp Pyrrolidine als dipeptidyl peptidase inhibitoren
ATE355064T1 (de) 2001-10-26 2006-03-15 Angeletti P Ist Richerche Bio Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
US7642277B2 (en) 2002-12-04 2010-01-05 Boehringer Ingelheim International Gmbh Non-nucleoside reverse transcriptase inhibitors
WO2004071448A2 (fr) 2003-02-12 2004-08-26 Transtech Pharma Inc. Derives d'azole substitues comme agents therapeutiques
EA014685B1 (ru) 2003-04-25 2010-12-30 Джилид Сайэнс, Инк. Фосфонатсодержащие антивирусные соединения (варианты) и фармацевтическая композиция на их основе
US7186747B2 (en) 2004-02-27 2007-03-06 Schering Corporation Compounds as inhibitors of hepatitis C virus NS3 serine protease
US7453002B2 (en) 2004-06-15 2008-11-18 Bristol-Myers Squibb Company Five-membered heterocycles useful as serine protease inhibitors
US7429604B2 (en) 2004-06-15 2008-09-30 Bristol Myers Squibb Company Six-membered heterocycles useful as serine protease inhibitors
AU2005330489B2 (en) 2004-07-27 2011-08-25 Gilead Sciences, Inc. Nucleoside phosphonate conjugates as anti HIV agents
US8067587B2 (en) 2005-07-28 2011-11-29 Lenroc Company Process for the production of monoalkali metal cyanurates
US20070032469A1 (en) 2005-08-05 2007-02-08 Astrazeneca Ab Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators
NZ568595A (en) 2005-12-14 2010-04-30 Bristol Myers Squibb Co Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors
EP2010493B1 (fr) 2006-04-12 2016-01-27 Merck Sharp & Dohme Corp. Composés de pyridylamide antagonistes des canaux calciques de type t
US7647464B2 (en) 2006-04-28 2010-01-12 At&T Intellectual Property, I,L.P. Methods, systems, and products for recording media to a restoration server
WO2008013622A2 (fr) 2006-07-27 2008-01-31 E. I. Du Pont De Nemours And Company Amides azocycliques fongicides
US8124811B2 (en) 2007-03-20 2012-02-28 Allylix, Inc. Fragrance and methods for production of 5-epi-β-vetivone, 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-2,6-dien-8-one, and 2-isopropyl-6,10-dimethyl-spiro[4.5]deca-1,6-dien-8-one
EP2139883A4 (fr) 2007-03-23 2011-06-22 Univ Massachusetts Inhibiteurs de la protéase du vih-1
WO2009005677A2 (fr) 2007-06-29 2009-01-08 Gilead Sciences, Inc. Composés antiviraux
CA2693044C (fr) 2007-07-12 2017-03-14 Tibotec Pharmaceuticals Forme cristalline de of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2 pyrimidinyl]amino]benzonitrile
AU2008277377B2 (en) 2007-07-19 2013-08-01 Msd Italia S.R.L. Macrocyclic compounds as antiviral agents
AU2008317353B2 (en) 2007-10-24 2014-08-07 Merck Sharp & Dohme Llc Heterocycle phenyl amide T-type calcium channel antagonists
JP2011500808A (ja) 2007-10-24 2011-01-06 メルク・シャープ・エンド・ドーム・コーポレイション 複素環アミドｔ型カルシウムチャネルアンタゴニスト
EA019259B1 (ru) 2007-11-16 2014-02-28 Джилид Сайенсиз, Инк. Ингибиторы репликации вируса иммунодефицита человека
US8324199B2 (en) 2008-03-13 2012-12-04 Bristol-Myers Squibb Company Pyridazine derivatives as factor xia inhibitors
RS53347B (sr) 2008-12-09 2014-10-31 Gilead Sciences, Inc. Modulatori toll-sličnih receptora
CN102414217A (zh) 2009-02-25 2012-04-11 彼格泰格私人有限公司 用于检测基孔肯雅病毒的探针和引物
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US20110274648A1 (en) 2009-11-11 2011-11-10 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
WO2011094890A1 (fr) 2010-02-02 2011-08-11 Argusina Inc. Dérivés phénylalanines et leur utilisation comme modulateurs non peptidiques du récepteur de glp-1
WO2011139637A1 (fr) 2010-05-03 2011-11-10 Philadelphia Health & Education Corporation Modulateurs à petite molécule de stabilité de capside de vih-1 et procédés pour ceux-ci
WO2011143772A1 (fr) 2010-05-21 2011-11-24 Boehringer Ingelheim International Gmbh Inhibiteurs de la réplication du vih
EP2588455B1 (fr) 2010-07-02 2018-04-04 Gilead Sciences, Inc. Dérivés de l'acide 2-quinolinyl-acétique en tant que composés antiviraux hiv
MX2012015097A (es) 2010-07-02 2013-05-28 Gilead Sciences Inc Derivados de acido naft-2-ilacetico para tratar sida.
CN102464654B (zh) 2010-11-12 2016-01-13 上海泓博智源医药技术有限公司 抗病毒化合物
SI2688403T1 (sl) 2011-03-23 2017-08-31 Trevena, Inc. Ligandi opioidnih receptorjev in metode uporabe in izdelave istega
UA111841C2 (uk) 2011-04-21 2016-06-24 Гіліад Сайєнсіз, Інк. Сполуки бензотіазолу та їх фармацевтичне застосування
AU2012278976B2 (en) 2011-07-06 2017-05-11 Gilead Sciences, Inc. Compounds for the treatment of HIV
CN102863512B (zh) 2011-07-07 2016-04-20 上海泓博智源医药技术有限公司 抗病毒化合物
ES2608871T5 (es) 2011-08-16 2024-04-04 Gilead Sciences Inc Alafenamide hemifumarate de tenofovir
US9399645B2 (en) 2011-12-20 2016-07-26 Boehringer Ingelheim International Gmbh Inhibitors of HIV replication
UY34750A (es) 2012-04-20 2013-11-29 Gilead Sciences Inc ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
GB201213087D0 (en) 2012-07-24 2012-09-05 Medical Res Council Inhibition of HIV-1 infection
WO2014028931A2 (fr) 2012-08-17 2014-02-20 Brandeis University Composés et procédés de traitement d'infections microbiennes gastro-intestinales de mammifère
EA030003B1 (ru) 2012-12-21 2018-06-29 Джилид Сайэнс, Инк. Полициклическое карбамоилпиридоновое соединение и его фармацевтическое применение для лечения вич-инфекции
PE20151063A1 (es) 2012-12-27 2015-08-03 Japan Tobacco Inc DERIVADO SUSTITUIDO DE ESPIROPIRIDO[1,2-a]PIRAZINA Y USO MEDICO DEL MISMO COMO INHIBIDOR DE LA INTEGRASA DEL VIH
ES2642265T3 (es) 2013-01-09 2017-11-16 Gilead Sciences, Inc. Compuestos terapéuticos para el tratamiento de infecciones virales
TW201443037A (zh) 2013-01-09 2014-11-16 Gilead Sciences Inc 治療用化合物
US9220710B2 (en) 2013-01-09 2015-12-29 Gilead Sciences, Inc. Therapeutic compounds
EP2769722A1 (fr) 2013-02-22 2014-08-27 Ruprecht-Karls-Universität Heidelberg Composés utilisés pour inhiber un assemblage de capside du VIH
US20140296266A1 (en) 2013-03-01 2014-10-02 Gilead Sciences, Inc. Therapeutic compounds
TWI694071B (zh) * 2013-03-01 2020-05-21 美商基利科學股份有限公司 治療反轉錄病毒科(Retroviridae)病毒感染之治療性化合物
GB201312991D0 (en) 2013-07-19 2013-09-04 Isis Innovation Process
AU2014340110B2 (en) 2013-10-24 2018-07-12 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2015130966A1 (fr) 2014-02-28 2015-09-03 Gilead Sciences, Inc. Agents antiviraux
US10202353B2 (en) 2014-02-28 2019-02-12 Gilead Sciences, Inc. Therapeutic compounds
EP3186239B1 (fr) * 2014-08-29 2018-10-10 Gilead Sciences, Inc. Agents antiretroviraux
US9855230B2 (en) 2014-09-09 2018-01-02 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
SG11201705192PA (en) 2014-12-24 2017-07-28 Gilead Sciences Inc Fused pyrimidine compounds for the treatment of hiv
TWI699355B (zh) 2014-12-24 2020-07-21 美商基利科學股份有限公司 喹唑啉化合物
US10221129B2 (en) 2015-04-23 2019-03-05 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
WO2016172425A1 (fr) 2015-04-23 2016-10-27 Viiv Healthcare (No.5) Limited Inhibiteurs de la réplication du virus d'immunodéficience humaine
PL3456717T3 (pl) 2015-07-06 2021-10-25 Gilead Sciences, Inc. Pochodna 4,6-diaminochinolino-3-karbonitrylu jako modulator cot (cancer osaka thyroid) do leczenia choroby zapalnej
US10171985B1 (en) 2015-07-22 2019-01-01 Ginko LLC Method and apparatus for data sharing
CN119462611A (zh) 2016-08-19 2025-02-18 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
AR110922A1 (es) 2017-02-06 2019-05-15 Gilead Sciences Inc Compuestos inhibidores del vih
TW201906834A (zh) 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
AR112412A1 (es) 2017-08-17 2019-10-23 Gilead Sciences Inc Formas de sal de colina de un inhibidor de la cápside del vih
JP7083398B2 (ja) 2018-02-15 2022-06-10 ギリアード サイエンシーズ， インコーポレイテッド ピリジン誘導体およびｈｉｖ感染を処置するためのその使用
EP3752496B1 (fr) 2018-02-16 2023-07-05 Gilead Sciences, Inc. Procédés et intermédiaires pour préparer un composé thérapeutique utile dans le traitement d'une infection virale par retroviridae
US10911396B2 (en) 2018-06-28 2021-02-02 Paypal, Inc. Mid-tier messaging system
KR20210033492A (ko) 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
CA3157275C (fr) 2019-11-26 2026-02-10 Gilead Sciences, Inc. Inhibiteurs de capside pour la prevention du vih
TWI858267B (zh) 2020-06-25 2024-10-11 美商基利科學股份有限公司 用於治療hiv之蛋白殼抑制劑

Also Published As

Publication number Publication date
JP2020111592A (ja) 2020-07-27
PH12021552802A1 (en) 2022-07-04
CY2022039I1 (el) 2023-01-27
CA3021227A1 (fr) 2018-02-22
FR22C1063I1 (fr) 2023-02-03
AU2017312102B2 (en) 2020-03-05
KR20230011471A (ko) 2023-01-20
JP6716785B2 (ja) 2020-07-01
US20200262815A1 (en) 2020-08-20
MA50673A (fr) 2020-08-05
CN109890808A (zh) 2019-06-14
KR102180740B1 (ko) 2020-11-20
PT3597646T (pt) 2023-09-11
CN119462611A (zh) 2025-02-18
SA519401123B1 (ar) 2022-11-09
AU2023271739B2 (en) 2025-08-21
PL3347352T3 (pl) 2019-12-31
US20240376077A1 (en) 2024-11-14
NZ763251A (en) 2025-02-28
CY1122296T1 (el) 2021-01-27
BR112018071678A2 (pt) 2019-02-19
TW201922711A (zh) 2019-06-16
DK3597646T3 (da) 2023-09-04
JP2023011754A (ja) 2023-01-24
CR20190084A (es) 2019-05-02
FI3597646T3 (fi) 2023-09-07
TWI664966B (zh) 2019-07-11
NL301212I2 (nl) 2023-04-06
ECSP19011209A (es) 2019-02-28
US10654827B2 (en) 2020-05-19
ZA201901430B (en) 2021-09-29
ES2954514T3 (es) 2023-11-22
PL3597646T3 (pl) 2023-12-11
SG10201912535VA (en) 2020-02-27
AU2021221855A1 (en) 2021-09-23
EP3597646A1 (fr) 2020-01-22
IL264644B (en) 2019-09-26
SI3347352T1 (sl) 2019-08-30
PE20211427A1 (es) 2021-08-03
AU2021221855B2 (en) 2023-08-31
KR20240070646A (ko) 2024-05-21
LUC00292I2 (fr) 2025-05-12
DOP2019000033A (es) 2019-03-15
HRP20231018T1 (hr) 2023-12-08
MX2018012905A (es) 2019-01-30
US10071985B2 (en) 2018-09-11
AU2020202331B2 (en) 2021-05-27
JP2019528280A (ja) 2019-10-10
PE20190910A1 (es) 2019-06-26
EP3347352A1 (fr) 2018-07-18
NZ791323A (en) 2025-03-28
CY2022039I2 (el) 2023-01-27
US20180370950A1 (en) 2018-12-27
SI3597646T1 (sl) 2023-10-30
SG11201808944QA (en) 2018-11-29
DK3347352T3 (da) 2019-08-26
CO2019001379A2 (es) 2019-02-19
PH12019500335A1 (en) 2019-11-11
ES2746374T3 (es) 2020-03-05
AU2020202331C1 (en) 2021-08-26
MX369307B (es) 2019-11-05
TW202342449A (zh) 2023-11-01
US20180051005A1 (en) 2018-02-22
EP3597646B1 (fr) 2023-06-21
WO2018035359A1 (fr) 2018-02-22
AU2025271141A1 (en) 2025-12-18
BR122020001791B1 (pt) 2022-01-25
JP2021008516A (ja) 2021-01-28
CN111793061B (zh) 2024-11-26
NL301212I1 (fr) 2023-01-12
HUE063811T2 (hu) 2024-02-28
KR20190039431A (ko) 2019-04-11
MA42795B1 (fr) 2019-08-30
JOP20180098A1 (ar) 2018-02-19
TW202138365A (zh) 2021-10-16
NZ750706A (en) 2020-07-31
JOP20180123A1 (ar) 2019-01-30
KR20250085838A (ko) 2025-06-12
LT3347352T (lt) 2019-08-12
EP3347352B1 (fr) 2019-07-03
HUE045137T2 (hu) 2019-12-30
JP2024170471A (ja) 2024-12-10
LTPA2023501I1 (fr) 2023-02-10
CN109890808B (zh) 2020-08-07
KR20200131351A (ko) 2020-11-23
UA121630C2 (fr) 2020-06-25
TW202504608A (zh) 2025-02-01
NZ791314A (en) 2025-03-28
CN111793061A (zh) 2020-10-20
TW201811327A (zh) 2018-04-01
HUS2200053I1 (hu) 2023-01-28
HK1256904B (en) 2020-07-17
US11993583B2 (en) 2024-05-28
TWI715944B (zh) 2021-01-11
AU2017312102A1 (en) 2019-03-07
TWI853404B (zh) 2024-08-21
PT3347352T (pt) 2019-09-24
AU2023271739A1 (en) 2023-12-14
MY191466A (en) 2022-06-28
EP4265299A2 (fr) 2023-10-25
FR22C1063I2 (fr) 2023-12-15
NO2022059I1 (no) 2022-12-16
LT3597646T (lt) 2023-09-25
EP4265299A3 (fr) 2024-01-17
UY37367A (es) 2018-03-23
CL2019000415A1 (es) 2019-06-21
CA3021227C (fr) 2020-11-03
LTC3347352I2 (fr) 2024-10-10
BR112018071678B1 (pt) 2021-01-26
AU2020202331A1 (en) 2020-04-23

Similar Documents

Publication Publication Date Title
MA42795A (fr) Composés thérapeutiques utiles pour le traitement prophylactique ou thérapeutique d'une infection par le virus du vih
NZ729150A (en) Antiretroviral agents
MA52948B1 (fr) Composés
MA39809B1 (fr) Derives de nucleoside substitues en 4' en tant qu'inhibiteurs de la transcriptase inverse du vih
MA41338A (fr) Composés de pyrazine pour le traitement de maladies infectieuses
EA202091113A1 (ru) Новые высокоактивные аминотиазолзамещенные индол-2-карбоксамиды, активные в отношении вируса гепатита b (hbv)
EA202092248A1 (ru) Замещенные соединения 4-аминоизоиндолин-1,3-диона, их композиции и способы лечения ими
MA35833B1 (fr) Dérivés de bétuline
EA201791872A1 (ru) Полициклические карбамоилпиридоновые соединения и их фармацевтическое применение
MA39721A (fr) Nouvelles héteroaryldihydropyrimidines condensées en position 6 pour le traitement et la prophylaxie d'une infection à virus de l'hépatite b
MA54386B1 (fr) Modulateurs de trex1
GEP20227353B (en) Tetracyclic heterocycle compounds useful as hiv integrase inhibitors
MA34968B1 (fr) Urées asymétriques et utilisations médicales de celles-ci
MA38315B1 (fr) Composés tétracycliques substitués par un hétérocycle et procédés pour les utiliser pour le traitement de maladies virales
EA201490213A1 (ru) Бензофурановые соединения для лечения инфекций вирусом гепатита с
MA39983A (fr) Dérivés de carboxamide
FR3033701B1 (fr) Nouvelles compositions antivirales pour le traitement de la grippe
MA39337A1 (fr) Modulateurs de pyrazines de gpr6
MA41311B1 (fr) Peptides antagonistes du cgrp
FR3058640B1 (fr) Composes pour leur utilisation dans le traitement de la grippe
EA201990295A1 (ru) Терапевтические соединения, которые можно применять для профилактического или терапевтического лечения инфекции вирусом вич
EA202192965A1 (ru) Новые индолизин-2-карбоксамиды, активные против вируса гепатита b (вгв)
EA202192969A1 (ru) Новые оксалилпиперазины, активные против вируса гепатита b (вгв)
EA202192967A1 (ru) Новые индол-2-карбоксамиды, активные против вируса гепатита b (вгв)
EP4037707A4 (fr) Composés pour le traitement du virus de l'immunodéficience humaine